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AbstrAct
Bladder cancer has an unexplained, high recurrence rate. Causes of recurrence 
might include the presence of sporadic tumor micro-foci in the residual urothelial 
tissue after surgery associated with an inverted ratio between intratumoral effector 
and regulatory T cell subsets. Hence, surgical specimens of both tumors and 
autologous, macroscopically/histologically free-of-tumor tissues were collected from 
28 and 20 patients affected by bladder or renal cancer, respectively. The frequencies 
of effector (IFNγ+ and IL17+ T cells) and regulatory (CD4+CD25hiCD127lo and 
CD8+CD28-CD127loCD39+ Treg) T cell subpopulations among tumor infiltrating 
lymphocytes were analyzed by immunofluorescence, while the gene expression 
of MAGE-A1 and MAGE-A2 tumor-associated antigens was studied by RT-PCR. The 
results show that both the T cell infiltrate and the frequency of MAGE-A1/A2 gene 
expression were comparable in tumors and in autologous free-of-tumor tissues in 
bladder cancer, while the autologous free-of-tumor renal tissues showed reduced T 
cell infiltrate and frequency of MAGE gene expression as compared to the autologous 
tumors. Importantly, the intra-tumor T effector/Treg cell ratio was consistently <1 
in bladder cancer patients (n. 7) who relapsed within two years, while it was always 
>1 in patients (n. 6) without recurrence (regardless of tumor stage) (P = 0.0006, 
Odds ratio = 195). These unprecedented findings clarify the pathogenic mechanism of 
bladder cancer recurrence and suggest that microscopically undetectable micro-foci of 
tumor may predispose to recurrence when associated with an inverted intratumoral 
T effector/Treg cell ratio.
INtrODUctION
Bladder carcinoma is the most common malignancy 
of the urinary tract and represents the ninth most common 
cancer worldwide [1]. The main therapeutic options 
for this disease include transurethral resection for non-
muscle-infiltrating stages, and radical cystectomy 
for more advanced stages [2]. Bladder cancer has an 
extremely high rate of recurrence. In fact, between 60% 
and 90% of patients with superficial disease and 50% 
to 65% of patients with muscle invasive disease relapse 
after surgery [3, 4, 5, 6]. The reason for this high rate of 
recurrence, distinctive of bladder cancer, is still unknown. 
We hypothesized that bladder cancer recurrence may be 
related to: a) sub-microscopic foci of tumor residual after 
surgery; b) the intratumoral prevalence of regulatory over 
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effector T cell subsets. 
In our study, the T lymphocyte infiltrate and the 
gene expression of tumor-associated antigens (TAA) were 
analyzed in specimens from tumoral and macroscopically/
histologically free-of-tumor autologous bladder tissues. 
For comparative purposes, identical analyses were 
performed on specimens from renal cancer, another 
genitourinary malignancy that does not present a high 
recurrence rate [7]. Concerning the T cell infiltrate, its 
composition (in terms of effector and regulatory T cell 
subsets) has been related to cancer prognosis [8, 9]. In 
particular, increased frequency of interferon-gamma 
(IFNγ) or interleukin (IL)17 positive cells [10, 11] and 
reduced frequency of T regulatory lymphocytes (Treg) 
[12, 13] among tumor infiltrating lymphocytes (TIL) 
were associated with a better prognosis. Hence, IFNγ+ 
and IL17+ T cells were selected as being representative 
of effector lymphocyte subsets, while both CD4+ and 
CD8+ Treg were taken into consideration as regulatory 
T cell subpopulations. Among the several subsets of 
CD8+ Treg [14], we concentrated on those phenotypically 
characterized as CD8+CD28-CD127loCD39hi because 
frequently present among TIL [15, 16]. The ratio between 
intratumoral effector and regulatory T cell subsets was 
correlated with recurrence in a cohort of 13 bladder cancer 
patients after a two-year follow-up.
With regard to TAA gene expression, two MAGE 
molecular subtypes (MAGE-A1 and MAGE-A2) were 
selected for our analyses since their presence has been 
reported in both bladder and renal cancers [17, 18]. 
The results of the study showed surprising 
comparability of both T lymphocyte infiltrate and 
TAA gene expression pattern between tumoral and 
macroscopically/histologically free-of-tumor tissues from 
bladders affected by cancer, while this was not the case 
for tumoral kidneys. Moreover, they revealed that the 
recurrence of bladder cancer was invariably associated 
with a T effector/Treg ratio <1.
rEsULts
circulating effector and regulatory t cell 
subpopulations in bladder and renal cancer 
patients
In order to comparatively analyze the relative 
frequency of effector and regulatory T cell subsets in 
bladder and renal cancer patients, initial studies were 
performed on circulating T cells. The frequencies of four 
effector T cell subsets, namely CD4+IFNγ+, CD8+IFNγ+, 
CD4+IL17+, CD8+IL17+ T lymphocytes, and two 
Treg subsets, CD4+CD25hiCD127lo and CD8+CD28-
CD127loCD39hi Treg, were comparatively analyzed in 
the peripheral blood of bladder and renal cancer patients. 
Figure 1 (panels A-D) shows that no significant differences 
concerning any of the effector T cell subpopulations were 
detected in the circulation between patients affected by the 
two types of tumor. Interestingly, a statistically significant 
increase in CD4+CD25hiCD127lo Treg frequency was 
observed among circulating lymphocytes from bladder 
cancer patients as compared to renal cancer patients 
(Figure 1, panels E and F). Comparable frequencies of 
each of the tested T cell subpopulations were observed in 
patients with TNM >2 and in those with TNM ≤2 (not 
shown).
Effector and regulatory T cell infiltrates in 
bladder and renal cancers
The absolute counts of intratumoral CD3+ T 
lymphocytes present in each specimen did not show 
significant differences between bladder and renal cancer 
(Supplementary Figure 1). The frequencies of all effector 
T cell subsets were comparable in the immune infiltrates 
from specimens of bladder and renal cancers (Figure 2, 
panels A-D). Interestingly, the frequency of intratumoral 
CD4+IFNγ+ T cells significantly correlated with that of 
intratumoral CD8+IFNγ+ T lymphocytes as well as of 
intratumoral CD4+IL17+ T cells in both types of tumor 
(Supplementary Figure 2), suggesting their coordinated 
homing to the tumor site. Comparable frequencies of CD4+ 
and CD8+ Treg were detected in both types of cancer 
(Figure 2, panels E and F), although a predominance of 
either CD4+ Treg or CD8+ Treg was observed in different 
specimens (Figure 2, panels G and H). Hence, these data 
indicate that both Treg subsets must be considered in order 
to achieve a realistic picture of the intratumoral regulatory 
T cell compartment. Interestingly, a significantly increased 
frequency of CD4+CD25hiCD127lo Treg was detected 
among TIL purified from bladder cancer samples as 
compared to those extracted from renal cancer samples 
(Figure 2, panels I and J). 
comparison of effector and regulatory t cell 
infiltrates between tumor and macroscopically/
histologically free-of-tumor tissues
In order to compare the T cell infiltrates present 
in the tumor with those of the autologous apparently 
free-of-tumor tissue, surgical specimens were collected 
from areas of the affected organ that macroscopically 
appeared free of disease. In parallel, the same areas of 
apparently normal tissues were histologically analyzed 
and no signs of tumor infiltration were detected (Figure 3, 
subpanels a, e, i, m). Preliminary analysis of the absolute 
cell counts showed comparable values of infiltrating 
CD3+ T cells in bladder cancers and in the apparently 
free-of-tumor bladder tissues, while significantly lower 
amounts of CD3+ T cells were observed in the apparently 
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Figure 1: Frequencies of circulating t cell subpopulations in bladder and renal cancer patients. Panels A, B, C and D 
refer to analyses performed on CD4+IFNγ+, CD8+IFNγ+, CD4+IL17+, and CD8+IL17+ T lymphocytes, respectively, comparing the 
frequencies of each of the above T cell subsets in bladder or renal cancer specimens; panels E and F refer to comparative analyses 
performed between CD4+CD25hiCD127lo and CD8+CD28-CD127loCD39hi Treg subsets derived from either bladder or renal cancer 
specimens, respectively; Black bars: analyses performed on cells from bladder cancer patients; open bars: analyses performed on cells from 
renal cancer patients.
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unaffected renal tissues with respect to renal cancers 
(Supplementary Figure 1). Importantly, the frequencies 
of all the effector T cell subsets were comparable in the 
tumoral and in the corresponding apparently free-of-tumor 
bladder tissues (Figure 4, panels A-D), while significantly 
lower frequencies of effector T cell subsets were found 
in the unaffected kidney tissue as compared to the 
corresponding, autologous renal cancer (Figure 4, panels 
E-H). Accordingly, the immunohistochemical staining 
with anti-CD3, CD4 and CD8 mAbs showed remarkable 
T cell infiltration in bladder and renal cancers as well as in 
the apparently free-of-tumor bladder tissue, while a rare T 
cell infiltrate was present in the apparently free-of-tumor 
kidney tissue (Figure 3).
Low amounts (<1% of total CD3+ T cells) of 
CD4+IFNγ+IL17+ and/or CD8+IFNγ+IL17+ T cell 
subsets were observed in 8 out of 18 tested bladder cancer 
patients and in 5 out of 17 tested renal cancer patients: 
no significant differences between tumoral and apparently 
free-of-tumor tissues, as well as between bladder and renal 
tissues were observed (not shown). 
A decreased frequency of CD4+CD25hiCD127lo 
Treg was present in the apparently free-of-tumor bladder 
tissue with respect to the autologous bladder cancer 
(Figure 4, panels I and J). Similarly to the effector T cell 
subsets, the frequencies of both CD4+CD25hiCD127lo 
and CD8+CD28-CD127loCD39hi Treg were significantly 
lower in the apparently unaffected renal tissue than in the 
autologous renal cancer tissue (Figure 4, panels K and L). 
MAGE-A1 and MAGE-A2 gene expression 
in tumor and autologous macroscopically/
histologically free-of-tumor tissues
In order to reveal micro-foci of tumor localization 
at the molecular level, the expression of two TAA 
genes, MAGE-A1 and MAGE-A2, which may be 
expressed by both bladder and renal cancers [17, 18], 
was comparatively analyzed in tumoral and autologous 
apparently free-of-tumor bladder and kidney tissues. The 
frequencies of gene expression of the two TAA genes were 
Figure 2: Frequencies of intratumoral t cell subpopulations in bladder and renal cancer patients. Panels A., b., c. and 
D. refer to analyses performed comparing the frequencies of CD4+IFNγ+, CD8+IFNγ+, CD4+IL17+, or CD8+IL17+ T lymphocytes, 
respectively, in bladder cancer specimens and renal cancer specimens; panels E. and F. refer to analyses performed comparing the 
frequencies of CD4+CD25hiCD127lo and CD8+CD28-CD127loCD39hi Treg subsets in bladder cancer specimens or in renal cancer 
specimens, respectively; panel G. each line associates the frequency values of CD4+CD25hiCD127lo and CD8+CD28-CD127loCD39hi 
Treg subsets detected in each single bladder cancer specimen; panel H. each line associates the frequency values of CD4+CD25hiCD127lo 
and CD8+CD28-CD127loCD39hi Treg subsets detected in each single renal cancer specimen; panels I. and J. refer to analyses performed 
comparing the frequencies of CD4+CD25hiCD127lo or CD8+CD28-CD127loCD39hi Treg subsets, respectively, in bladder cancer 
specimens and renal cancer specimens. 
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Figure 3: Hematoxylin-Eosin stain and immunohistochemistry for cD3+, cD4+, cD8+ t cells on. A. a poorly differentiated 
urothelial carcinoma of the bladder b., the autologous histologically free-of-tumor bladder tissue (both from patient #1), c. a papillary 
type II renal cell carcinoma and D. the autologous histologically free-of-tumor cortical renal tissue (both from patient #30). a, e, i, m: 
Haematoxylin-Eosin stain (4x magnification); b, f, j, n: immunohistochemistry using an anti-CD3 antibody (4x magnification); c, g, k, 
o: immunohistochemistry using an anti-CD4 antibody (4x magnification); d, h, l, p: immunohistochemistry using an anti-CD8 antibody 
(4x magnification). a-h: an intense T lymphocyte infiltrate is shown both in the tumour and the histologically free-of-tumor mucosa; 
lymphocytes are sparse or in nodular aggregates and localize between neoplastic cells as well as in the interstitium. In non-neoplastic 
mucosa a comparable infiltrate is seen both in the intraepithelial tissue and in the subepithelial connective tissue. i-p: While the tumor shows 
an evident T lymphocyte infiltrate, rare T lymphocytes are present in the non-neoplastic epithelium.
Figure 4: Frequencies of intratumoral t cell subpopulations in bladder cancers and autologous apparently free-of-
tumor bladder tissues as well as in renal cancers and autologous apparently free-of-tumor renal tissues. Panels A, B, C 
and D refer to analyses performed on CD4+IFNγ+, CD8+IFNγ+, CD4+IL17+, and CD8+IL17+ T lymphocytes, respectively, from bladder 
specimens; panels E, F, G, and H refer to analyses performed on CD4+IFNγ+, CD8+IFNγ+, CD4+IL17+, and CD8+IL17+ T lymphocytes, 
respectively, from renal specimens; panels I and J refer to analyses performed on CD4+CD25hiCD127lo and CD8+CD28-CD127loCD39hi 
Treg subsets, respectively, from bladder specimens; panels K and L refer to analyses performed on CD4+CD25hiCD127lo and CD8+CD28-
CD127loCD39hi Treg subsets, respectively, from renal specimens. Black bars: analyses performed on cells from tumor specimens; open 
bars: analyses performed on cells from apparently free-of-tumor tissues.
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comparable in bladder and renal cancers (Figure 5, panels 
A-C). Conversely, higher frequencies of MAGE-A1 and 
MAGE-A2 expression were observed in the bladder with 
respect to the renal apparently free-of-tumor tissue (Figure 
5, panels D-F). Accordingly, significant differences in 
MAGE-A1 and MAGE-A2 gene expression between the 
tumor and the apparently free-of-tumor tissue were only 
observed for renal but not bladder cancer (Figure 5, panels 
G-J). Interestingly, while expression of at least one of the 
two MAGE genes was detected in 100% of bladder and 
renal cancers (Figure 5, panel K), MAGE gene expression 
was a common feature for the apparently free-of-tumor 
bladder tissue (13 out of 14 positive cases) but not for the 
apparently free-of-tumor renal tissue (3 out of 11 positive 
cases) (Figure 5, panel L). 
T effector/Treg cell ratio in the tumor infiltrates 
of relapsing or non-relapsing bladder cancer 
patients
The observation of comparable T cell infiltrates 
and TAA gene expression pattern in bladder cancer and 
in autologous apparently free-of-tumor tissue suggests 
Figure 5: Frequencies of MAGE-A1 and MAGE-A2 gene expression in bladder and renal cancers as well as in bladder 
and renal apparently free-of-tumor tissues. A. frequency of bladder or renal tumor showing or not MAGE-A1 gene expression; b. 
frequency of bladder or renal tumors showing or not MAGE-A2 gene expression; c. frequency of detections on bladder or renal tumors 
that resulted positive or not for any MAGE gene expression; D. frequency of bladder or renal apparently free-of-tumor tissue showing 
or not MAGE-A1 gene expression; E. frequency of bladder or renal apparently free-of-tumor tissue showing or not MAGE-A2 gene 
expression; F. frequency of detections on bladder or renal apparently free-of-tumor tissue that resulted positive or not for any MAGE 
gene expression; G. comparisons of frequencies of tissue samples showing MAGE-A1 gene expression between bladder cancers and 
autologous apparently free-of-tumor bladder tissues; H. comparisons of frequencies of tissue samples showing MAGE-A2 gene expression 
between bladder cancers and autologous apparently free-of-tumor bladder tissues; I. comparisons of frequencies of tissue samples showing 
MAGE-A1 gene expression between renal cancers and autologous apparently free-of-tumor renal tissues; J. comparisons of frequencies 
of tissue samples showing MAGE-A2 gene expression between renal cancers and autologous apparently free-of-tumor renal tissues; K. 
frequencies of bladder or renal tumors showing positivity or not for at least one of the two MAGE molecule gene expression; L: frequencies 
of apparently free-of-tumor bladder or renal tissues showing positivity or not for at least one of the two MAGE molecule gene expressions; 
M. Representative MAGE antigen gene expression analyses performed by RT-PCR on specimens from bladder cancer patient #15 and 
renal cancer patient #39. The figure shows the amplicons obtained after MAGE-A1, MAGE-A2, and GADPH (as positive control) cDNA 
amplification in tumors (T) and apparently free-of-tumor tissues (N) run on agarose gel. Panels A-L: Open bars indicate presence of MAGE 
antigen gene expression while black bars indicate absence of MAGE antigen gene expression. 
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that sub-microscopic foci of tumor cells are sparse in 
the urothelium of tumoral bladders, predisposing to 
recurrence. However, this finding does not explain why 
not all bladder cancer patients relapse. Keeping in mind 
the possible role that the intratumoral T cell infiltrate may 
play in tumor recurrence, we comparatively analyzed 
its composition in samples taken from 13 patients who 
relapsed (n. 7) or not (n. 6) within two years from surgery. 
To this aim, the ratio between the sum of frequencies of 
the two effector T cell subsets and that of the two Treg 
subpopulations was calculated for each patient. As shown 
in Table 1 and in Figure 6, the intratumoral T effector/
Treg cell ratio was consistently <1 in patients who 
relapsed, while it was always >1 in patients who did not 
relapse, regardless of tumor stage. Interestingly, neither 
the frequency nor the absolute number of total Treg 
differed significantly between patients with or without 
relapse (not shown), underlying the need of taking into 
consideration the ratio between effector and regulatory 
T cell subpopulations (and not just single populations) in 
order to achieve a reliable prognostic marker.
DIscUssION
The results of the present study show that: a) the 
frequencies of effector T lymphocyte subpopulations, both 
in the circulation and in tumor infiltrates, are comparable 
in patients affected by bladder and renal cancers; b) CD4+ 
Treg frequency is higher in bladder cancer patients than in 
renal cancer patients, both in the circulation and in tumor 
infiltrates; c) the macroscopically/histologically free-of-
tumor bladder tissue peculiarly presents a T lymphocyte 
infiltrate whose composition is comparable to what is 
observed in autologous bladder cancer; d) the apparently 
Table 1: Calculation of the Teffector/Treg cell ratio in bladder cancer patients affected or not by recurrence within two 
years from surgery
Figure 6: T effector/Treg cell ratio in bladder cancer 
patients with and without recurrence two years after 
the surgery. A. Comparison between the T effector/Treg cell 
ratio of patients with recurrence and that of patients without 
recurrence; b. contingency analysis on the frequencies of 
recurrence or non-recurrence in patients with T effector/Treg cell 
ratios either >1 or < 1.
*: Data are expressed as percentages of CD3+ T lymphocytes
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table 2: Pathological features of patients enrolled in the study
Patient # Tumor histology Grading TNM
1 Bladder carcinoma 2 1a
2 Bladder carcinoma 3 1
3 Bladder carcinoma 3 3a
4 Bladder carcinoma 3 Tis
5 Bladder carcinoma 3 3
6 Bladder carcinoma 2 2
7 Bladder carcinoma 3 Tis
8 Bladder carcinoma 3 2
9 Bladder carcinoma 3 2
10 Bladder carcinoma 3 3
11 Bladder carcinoma 3 3b
12 Bladder carcinoma 3 Tis
13 Bladder carcinoma 3 1
14 Bladder carcinoma 3 3a
15 Bladder carcinoma 3 3b
16 Bladder carcinoma 3 3b
17 Bladder carcinoma 2 Ta
18 Bladder carcinoma 3 3
19 Bladder carcinoma 3 3b
20 Bladder carcinoma 3 4b
21 Bladder carcinoma 3 3b
22 Bladder carcinoma 3 2
23 Bladder carcinoma 3 4a
24 Bladder carcinoma 3 3b
25 Bladder carcinoma 2 Tis
26 Bladder carcinoma 2 Tis
27 Bladder carcinoma 3 3a
28 Bladder carcinoma 3 3b
29 Renal cell carcinoma 3 3a
30 Renal cell carcinoma 2 3a
31 Renal cell carcinoma 3 2
32 Renal cell carcinoma 4 2
33 Renal cell carcinoma 4 3a
34 Renal cell carcinoma 3 1
35 Renal cell carcinoma 4 3a
36 Renal cell carcinoma 3 1
37 Renal cell carcinoma 3 1
38 Renal cell carcinoma 2 2b
39 Renal cell carcinoma 3 3
40 Renal cell carcinoma 3 1a
41 Renal cell carcinoma 2 2
42 Renal cell carcinoma 3 3a
43 Renal cell carcinoma 2 3
44 Renal cell carcinoma 2 2
45 Renal cell carcinoma 4 3a
46 Renal cell carcinoma 2 1b
47 Renal cell carcinoma 3 3b
48 Renal cell carcinoma 2 1b
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free-of-tumor bladder tissue peculiarly shows a pattern of 
TAA gene expression comparable to that of the autologous 
bladder cancer; e) the intratumoral T effector/Treg cell 
ratio in bladder cancer patients with disease recurrence is 
invariably <1, while it is always >1 in patients without 
recurrence.
Although considerable progress has been made 
on bladder cancer pathogenesis [19-22], the high rate of 
bladder cancer recurrence is still unexplained [23, 24]. 
Cancer recurrence is likely related to tumor immune 
escape, a process that is at least partially dependent on an 
imbalance between effector and regulatory T cell function 
[25]. Accordingly, cancer prognosis has been related to the 
degree of tumor infiltration by effector and/or regulatory 
T cells [26, 27]. These observations suggest that the 
tumor could influence the T cell infiltrate composition. 
Subsequently, the identification in an apparently free-of-
tumor tissue of a T cell infiltrate resembling, in terms of 
T lymphocyte subset composition, what is present in the 
autologous tumor may indicate the presence of not yet 
histologically detectable foci of tumor cells (an event that 
in bladder cancer may be due to a genetic predisposition 
of the transitional epithelium [28] and/or to the early 
spreading of sub-microscopic metastases within the 
transitional epithelium). We considered the analysis of the 
T cell infiltrate as an indirect tool to reveal the presence 
of sub-microscopic foci of tumors in the apparently free-
of-tumor tissue from bladders affected by tumor. For 
comparative purposes, the same analyses were performed 
on specimens from kidneys affected by renal cancer. 
Interestingly, the frequencies of effector (considered as 
IFNγ+ and IL17+) T cell subpopulations were comparable 
in the two tumors: this likely rules out the possibility that 
a different degree (or quality) of the anti-tumor immune 
response might be responsible for the high recurrence 
rate that is distinctive of bladder cancer alone. Instead, 
the frequency of CD4+ Treg was lower in renal cancer 
compared to bladder cancer indicating that the level of 
tumor infiltration by Treg may have pathogenic relevance. 
Since CD4+ Treg frequency was found to be increased 
both in the circulation and at the tumor site in bladder 
cancer patients, as compared to what was observed in 
renal cancer patients, it is likely that both the mechanisms 
of CD4+ Treg in situ generation (at the tumor site) and 
recruitment from the periphery could be at play in bladder 
cancer patients. 
The fact that amount and composition of the T cell 
infiltrates were comparable in the tumor mass and in the 
apparently free-of-tumor bladder tissue suggests that 
similar antigenic patterns were present at both sites. The 
exception constituted by CD4+ Treg, whose intratumoral 
frequency was greater than that of the apparently free-
of-tumor tissue, may reflect the need for a critical size in 
order the tumor could efficiently generate/recruit Treg. 
The T cell infiltrate in renal cancer differed between the 
tumor and the histologically free-of-tumor autologous 
renal tissue. These findings indicate that the presence of 
a comparable T cell infiltrate in both the apparently non-
tumoral tissue of bladders affected by tumor and in the 
tumor itself is a specific prerogative of bladder cancer, 
likely related to the presence of sub-microscopic foci of 
tumor cells. 
In order to molecularly reveal these sub-microscopic 
tumor foci, we comparatively searched for the expression 
of genes coding for TAA, such as MAGE-A1 and 
MAGE-A2 [17, 18] in the tumors and in the autologous 
free-of-tumor bladder or renal tissues. While the pattern of 
TAA gene expression in the macroscopically/histologically 
free-of-tumor bladder tissue was comparable to that of the 
autologous tumor mass, this was not the case for the un-
diseased renal tissue. This further supports the presence of 
tumor cells in the context of the apparently non-tumoral 
bladder, but not renal, tissue. 
These results do not yet explain why only a certain 
percentage of patients relapse. Importantly, we observed 
that only patients with an inverted T effector/Treg cell 
ratio relapsed. This likely suggests that the multi-focal 
feature of bladder cancer may result in recurrence only 
when there is a local impairment of anti-tumor immunity 
due to overwhelming immunoregulation. Moreover, 
this unprecedented finding proposes the intratumoral T 
effector/Treg cell ratio as a new, sensitive biomarker of 
bladder cancer recurrence that, if validated in a broader 
series, could lead to a revision of both prognostic and 
therapeutic standards of bladder cancer. 
MAtErIALs AND MEtHODs
subjects
Twenty-eight patients affected by bladder cancer 
and 20 patients affected by renal cancer were enrolled 
at the Urology Clinic of the IRCCS – AOU San Martino 
– IST hospital of Genoa (Table 2). None of the bladder 
cancer patients had been treated with BCG at the time of 
enrollment. We collected a heparinized peripheral blood 
sample before surgery, a surgical specimen from the tumor 
mass, and a surgical specimen from an autologous area 
of macroscopically free-of-tumor bladder or renal tissue 
from each patient. A portion of the specimen from the 
macroscopically free-of-tumor tissue area was separated 
from the part on which immunological and molecular tests 
were performed, and was analyzed histologically. 
To avoid the risk of compromising the diagnostic 
value of surgically excised material, only small (≈5mm 
diameter size) tissue specimens were collected, although 
this choice somewhat limited the possibility to perform a 
more comprehensive array of immunological analyses and 
in some cases made it impossible to carry out the whole 
panel of scheduled tests in each single tissue sample. The 
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study was approved by the local ethics committee; all 
patients and controls enrolled in the study provided written 
informed consent. 
Purification of peripheral blood mononuclear 
cells (PBMC) and tissue lymphocyte infiltrates
PBMC were purified from heparinized blood 
samples by centrifugation on Ficoll-Hypaque gradient 
(Biochrom AG, Berlin, Germany) for 30 minutes at 1800 
rpm.
Lymphocytes from surgical specimens were purified 
by filtering minced tissues using a sterile cell strainer 
(Falcon, BD Biosciences, San Josè CA) and running the 
collected cells on Ficoll gradient.
Monoclonal antibodies (mAb) and 
immunofluorescence analyses
Cell expression of membrane antigens was tested 
by immunofluorescence analysis performed either on 
PBMC or on tissue lymphocyte infiltrates (1x105 cells in 
100 µl of PBS). Cells were incubated with specific mAbs 
at 4°C for 30 minutes in the dark. The following mAbs 
were used: fluorescein isothiocyanate (FITC) conjugated 
anti-CD45RA (Becton Dickinson, (BD) Biosciences, San 
Josè CA), phycoerythrin (PE) conjugated anti-CD127 
(e-Biosciences, San Diego, CA), Peridinin Chlorophyll 
Protein Complex-cyanin 5.5 PerCPCy5.5conjugated anti-
CD28 (eBioscience), Pe-Cy7 conjugated anti-CD25 (BD), 
allophycocyanin (APC) conjugated anti-CD39 (BD), 
allophycocyanin (APC)-cyanin (Cy) 7 conjugated anti-
CD3 and eFluor 450 conjugated anti-CD8 (e-Biosciences). 
Fluorochrome-conjugated isotype matched mAbs were 
used as controls (Becton Dickinson, BD Biosciences, 
San Josè CA). Following the staining procedures the 
cells were analyzed by a FACSCanto II flow cytometer 
(BD Biosciences) using FACS DIVA software (BD 
Biosciences).
Intracellular staining
The intracellular production of IFNγ and of IL17A 
by T lymphocytes from PBMC and tissue infiltrates was 
analyzed as follows: the cells (resuspended in culture 
medium conditioned with 10% autologous plasma at 
a concentration of 1 x 107/ml) were stimulated with 
phorbol-12-myristate-13-acetate (PMA 50 ng/ml, Sigma) 
and ionomycin (2 µg/ml, Sigma) for 5 hours at 37 °C. 
Brefeldin A (BFA 10 µg/ml, Sigma) was added to the 
cells for the last 4 hours of incubation. After washings, 
the samples were stained with fluorochrome-conjugated 
mAbs specific for surface markers [PerCPCy5.5 anti-CD3 
(BD), APCCy7 anti-CD8 (e-Biosciences) and Violet Live/
Dead Fixable Dead Cell stain (Life Technologies, CA, 
USA)], before fixing and permeabilizing the lymphocytes 
with the Cytofix/Cytoperm kit (BD Bioscience) following 
the manufacturer’s instructions. The cells were washed in 
Perm-Wash buffer (BD Bioscience) and incubated with Pe-
Cy7 anti-IFNγ (BD) or FITC anti-IL17A (e-Biosciences) 
mAbs. Thereafter, the samples were washed in Perm-Wash 
buffer, fixed with FACS Lysing solution (BD Bioscience) 
and stored at 4 °C. The cytokine profile was analyzed 
using a FACS Canto II flow cytometer (BD Bioscience) 
by the FACS DIVA software. The gating strategy for 
phenotypic analyses is shown in Supplementary Figure 3.
Expression of MAGE genes in tumor and in non-
tumoral bladder or renal tissues
Total RNA was extracted from frozen tissue 
samples using Omnizol reagent (EuroClone, United 
Kingdom,UK) according to the manufacturer’s 
instructions. For each sample, RNA was resuspended 
in 50μl RNAse free water before determining quality 
and concentration by Thermo Scientific NanoDrop 
1000 (Thermo Scientific, Wilmington, MA, USA). All 
these samples were treated with 6 U DNase I (Promega, 
Madison, WI, USA) and reverse transcription was carried 
out on 500 ng of total RNA using the Thermo Scientific 
RevertAid Reverse Transcriptase (Thermo Scientific, 
Wilmington, MA, USA). The following oligonucleotide 
pairs were used (sense and antisense, respectively): 
MAGE-A1, 5’-CGGCCGAAGGAACCTGACCCAG-3’ 
and 5’-GCTGGAACCCTCACTGGGTTGCC-3’; 
MAGE-A2, 5’-AAGTAGGACCCGAGGCACTG-3’ 
and 5’-GAAGAGGAAGAAGCGGTCTG-3’; 
GADPH, 5’-GGCATCCTGGGCTACACTGA-3’ and 
5’-TGGTGGTCCAGGGGTCTT-3’. Classical RT-
PCR amplification was performed by DreamTaq DNA 
polymerase (Fermentas, Amherst NY, USA). The cycling 
conditions were 5 min at 96 °C, 37 cycles of 45s at 94 
°C, 45s at 60 °C, 1 min at 72 °C, with a final extension 
of 10 min at 72 °C. We used normalization with GADPH 
expression to quantify PCR products before testing MAGE 
gene expression; PCR products were checked by sequence 
analysis.
Histology and immunohistochemistry assessments
For each specimen, a specular sample of neoplastic 
or normal tissues that had been used to perform 
immunological and molecular analyses were fixed in 10% 
buffered formalin and then routinely processed in paraffin.
Four 4 μm thick serial sections were freshly 
cut from each paraffin block by microtome [29]. One 
section was stained with hematoxylin and eosin and the 
other three sections were mounted on SuperFrost Plus 
slides (Thermo Scientific, Braunschweig, Germany) for 
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immunohistochemistry analysis.
Sections for immunohistochemistry were 
dried, deparaffinized and rehydrated. Endogenous 
peroxidase was blocked with 5% H2O2 for 10 minutes. 
Immunoreactions were performed using the automated 
BenchMark XT immunostainer® (Ventana Medical 
Systems, Arizona, USA). Standard heat-based antigen 
retrieval was performed for 30 minutes (when needed). 
The iVIEWTM DAB detection kit (Ventana Medical 
Systems, Arizona, USA), which is a streptavidin-biotin 
based indirect method, was used. After immunostaining, 
slides were counterstained with hematoxylin and 
coverslipped. All reactions were carried out on the 
same day on consecutive runs. Slides were evaluated 
simultaneously by three observers (LM, FG, MC) who 
were blinded to the patient’s clinical course. 
The following antibodies were used:
- anti-CD3 (SP7 clone, ImmunomarkersVentana, 
prediluted) for T-lymphocyte evaluation;
- anti-CD4 (SP35 clone, Cell Marque, dilution 
1:10) for CD4+ T lymphocyte evaluation;
- anti-CD8 (SP47 clone, Cell Marque, prediluted) 
for CD8+ T lymphocyte evaluation.
Histology and immunohistochemistry assessments 
were performed using a Leica DMD108 digital 
microimaging network instrument equipped with Leica 
Hi Plan 4X objective. 
statistical analysis
Statistically significant differences between mean 
values were analyzed by the Mann-Whitney test for 
nonparametric values or by the paired t test. Correlations 
between variables were analyzed by the Spearman 
correlation test. Statistically significant differences 
between frequencies were analyzed by Fisher’s exact test. 
Differences were considered statistically significant when 
P < 0.05. The statistical analyses were performed using the 
GraphPad Prism 4.0 Software (GraphPad Software, Inc, 
La Jolla, CA).
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